Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes

Diabetes Care

Volumn 23, Issue 5, 2000, Pages 639-643

  Ratner, Robert E ^a   Hirsch, Iri B ^b   Neifing, James L ^c   Garg, Satish K ^d   Mecca, Thomas E ^e   Wilson, Craig A ^e  

^a MedStar Clinical Research Center   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c Portland Diabet/Endocrinol Center   (United States)

^d UNIVERSITY OF COLORADO DENVER   (United States)

^e IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN GLARGINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0034033028     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.5.639     Document Type: Article

References (18)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
3. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1995
4. Cryer PE: Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 43: 1378-1389, 1994
5. Hirsch IB: Intensive treatment of type 1 diabetes. Med Clin North Am 82:689-719, 1998
6. Rosskamp R, Park G: Long-acting insulin analogs. Diabetes Care 22 (Suppl. 2): B109-B113, 1999
7. Home P: Insulin glargine: the first clinically useful extended-acting insulin in half a century. Exp Opinion Invest Drugs 8:307-314, 1999
8. Peters A, Klose O, Hefty R, Keck F, Kerner W: The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type I diabetes treated with human insulin. Diabet Med 12:925-930, 1995
9. Hilgenfeld R, Dorschug M, Geisin K, Neubauer HP, Ohermeier R, Seipke G, Berchthold H: Controlling insulin bioavailability by crystal contact engineering (Abstract). Diabetologia 35 (Suppl. 1):A193, 1992
10. Siepke G, Geisen K, Neubauer HP, Pittius C, Pittius C, Rosskamp R, Schwabe D: New insulin preparations with prolonged action profiles: A21-modified arginine insulins (Abstract). Diabetologia (Suppl. 1):A4, 1992
11. Hilgenfeld R, Dorshug M, Geisen K, Neubauer H, Obermeier R, Seipke G, Berchtold H: Controlling insulin bioavailability by crystal contact engineering (Abstract). Diabetologia 35 (Suppl. 1):A193, 1992
12. Coates PA, Mukherjec S, Luzio S, Srodzinski KA, Kurzhals R, Rosskamp R, Owens DR: Pharmacokinetics of a long-acting human insulin analogue (HOE901) in healthy subjects (Abstract). Diabetes 44 (Suppl. 1):130A, 1995
13. Soon PC, Matthews DR, Rosskamp R, Herz M, Kurzhals R: Profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology (Abstract). Diabetes 46 (Suppl. 1):161A, 1997
14. Dreyer M, Pein M, Schmidt C, Heidtmann B, Schlunzen M, Rosskamp D: Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arga(B31, B32)-human insulin (HOE71GT) with NPH-human insulin following subcutaneous injection by using euglycaemic clamp technique (Abstract). Diabetologia 37 (Suppl. 1):A78, 1994
15. Pieber TR, Eugene-Jolchine E, Derobert E: Efficacy and safely of insulin glargine in patients with type 1 diabetes: a four-week randomized NPH insulin-controlled trial (Abstract). Diabetes 47 (Suppl. 1):A62, 1998
16. Rosenstock J, Park G, Zimmerman J: Efficacy and safety of HOE 901 in patients with type 1 DM: a four-week randomized NPH insulin-controlled trial (Abstract). Diabetes 47 (Suppl. 1):A92, 1998
17. Raskin P, Park G, Zimmerman J, U.S. Study Group of HOE 901 in Type 2 Diabetes: The effect of HOE 901 on glycemic control in type 2 diabetes (Abstract). Diabetes 47 (Suppl. 1):A103, 1998
18. Matthews DR, Pfeiffer C, Multicenter HOE901 Research Group: Comparative clinical trial of a new long-acting insulin (HOE901) vs. protamine insulin demonstrates less nocturnal hypoglycemia (Abstract). Diabetes 47 (Suppl. 1):A101, 1998